Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Adicet Bio announced promising interim results from its Phase 1 study of ADI-001, a gamma delta CAR T cell therapy targeting B-cell Non-Hodgkin's Lymphoma. As of November 22, 2021, six patients received ADI-001, with an overall response rate (ORR) of 75% and a complete response (CR) rate of 50%. Notably, no serious adverse events were reported. The findings support the therapy's safety and potential effectiveness, highlighting its ability to offer an off-the-shelf treatment option. Further data is anticipated in the first half of 2022, showcasing the ongoing progress of Adicet's innovative platform.
Adicet Bio (Nasdaq: ACET) has announced a webcast on December 6, 2021, at 8:30 AM EST to present interim data from the Phase 1 study of ADI-001, an allogeneic gamma delta CAR T cell therapy targeting CD20 for B Cell Non-Hodgkin’s Lymphoma. This presentation will feature expert insights from Dr. Sattva Neelapu and Adicet's management team. The study aims to evaluate the safety and tolerability of ADI-001, marking a significant milestone in cancer treatment approaches.
Adicet Bio, Inc. (Nasdaq: ACET) announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors. With over 20 years of experience in oncology drug development, Kauffman is expected to enhance the company’s gamma-delta CAR-T therapy initiatives. His track record includes leadership roles in various biopharmaceutical firms and significant contributions to drug approvals. Adicet focuses on developing off-the-shelf gamma delta T cell therapies aimed at improving cancer treatment outcomes, which can potentially offer benefits over existing therapies.
Adicet Bio, a biotechnology company focused on allogeneic gamma delta T cell therapies, presented promising preclinical data for its candidate ADI-002 at the 36th SITC Annual Meeting. The GPC3-targeted CAR-T therapy showed significant antitumor activity in mice without off-target effects. Findings reveal ADI-002's potential for targeting solid tumors, particularly in liver and lung cancers, demonstrating potent cytotoxicity and enhanced proliferation. Notably, ADI-002 maintained a naïve-like phenotype and exhibited reduced alloreactive potential, positioning it as a strong candidate for further clinical evaluation.
Adicet Bio (ACET) reported a net loss of $14 million for Q3 2021, an improvement from $14.8 million in Q3 2020. The company's cash position increased to $192.2 million, sufficient to fund operations through mid-2023. Key developments include ongoing Phase 1 trials of ADI-001 for Non-Hodgkin's Lymphoma, with interim results expected by year-end, and a collaboration with Twist Bioscience to enhance CAR-T therapy development. G&A expenses decreased significantly to $5.2 million, while R&D expenses rose to $11.9 million as clinical activities ramped up.
Adicet Bio, Inc. (Nasdaq: ACET) announced that CEO Chen Schor will present at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 4:00 pm ET. The event details, including access to a live audio webcast, are available on Adicet's investor website. The company is focused on developing innovative allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response.
Adicet Bio, Inc. (Nasdaq: ACET) announced that its lead candidate, ADI-001, will be presented at the 63rd American Society of Hematology Annual Meeting on December 12, 2021. The presentation will detail the Phase 1 study aimed at evaluating the safety and tolerability of ADI-001, targeted at treating B Cell Malignancies. Interim clinical data is expected by the end of 2021. The abstract will also be published in Blood's November supplemental issue. Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer.
Adicet Bio, Inc. (Nasdaq: ACET) has announced the promotion of Blake Aftab, Ph.D., to Senior Vice President and Chief Scientific Officer. Dr. Aftab's new role focuses on expanding Adicet’s pipeline for cancer therapies, particularly in solid and hematologic tumors. His leadership is expected to enhance ongoing research, including the Phase 1 trial of ADI-001 for non-Hodgkin’s lymphoma. The company anticipates revealing interim data for ADI-001 later this year, marking a significant development in gamma delta CAR-T cell therapy.
Adicet Bio, Inc. (Nasdaq: ACET) announced a poster presentation for its allogeneic gamma delta CAR T cell therapy, ADI-002, at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. The poster, titled "ADI-002: an IL-15 armored allogeneic 'off-the-shelf' Vδ1 gamma delta CAR T cell therapy for solid tumors targeting glypican-3 (GPC3)," will be presented from November 12-14, 2021. This development emphasizes Adicet's focus on innovative cancer therapies and marks a significant step in its clinical strategy.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.